After five years of by-passing NICE, England's Cancer Drugs Fund will now be managed by the health technology assessor as the future of the siloed budget looks in doubt. 

This is according to NHS England's board meeting papers, where the health service's top commissioning body wants the CDF to become a 'managed access' fund for new cancer drugs, with “clear entry and exit criteria”. 

The papers add: “It [the CDF] would be used to resource those drugs which appear promising, but where NICE indicates that there is insufficient evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision.

For more details, go to: http://www.pmlive.com/pharma_news/nhs_england_hands_over_cancer_drug_fund_remit_to_nice_784328